Abbott has completed its acquisition of Exact Sciences, positioning the healthcare giant as a significant player in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. Exact Sciences is now a wholly owned Abbott subsidiary.
Chairman and CEO Robert B. Ford said the move will “expand access to important tools for early cancer detection and personalized treatments.” The acquired portfolio includes Cologuard for colorectal cancer screening, Oncotype DX for breast cancer treatment guidance, Oncodetect for molecular residual disease testing, and Cancerguard, a multi-cancer blood test. Abbott also gains a pipeline of next-generation screening diagnostics through the deal.
The completion of the transaction marks one of the largest healthcare acquisitions of the year, significantly broadening Abbott’s diagnostics capabilities beyond its existing portfolio and into the rapidly expanding field of cancer early detection.